Forging novel anticancer agents & cellular espionage using RALA

NPs have demonstrated effective anticancer activity in the HCT116 CRC cell line, meanwhile parallel studies on HT29 CRC and NCTC 929 cells, which exhibit reduced expression of dUTPase reveal that the lead candidate is significantly less effective. Indicating that the molecule is responsive to dUTPase expression and reflecting a degree of targeting and selectivity to specific cancer tissues, whilst unharming healthy tissues.

In vivo studies on BALB/c SCID mice reveal no significant acute negative health impacts on mouse behaviours, nor organ damage by histology and organ safety assays. Pharmacokinetic analysis reveals RALA potentiating effective delivery and internalisation into surrounding tissues, translating the in vitro findings. Ultimately, tumour growth delay studies have shown significant inhibition of tumour growth dynamics with tumour doubling time and prolonged median survival by two weeks. <br><i><br>Thesis embargoed until 31 July 2027</i>.